Quarterly report · Q2
4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥39.1bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥503m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.38 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.9 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥203.77 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥177m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥523m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 1117000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1062 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 521000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0496 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 481000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0457 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 368000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0350 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 315000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0300 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 314000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0299 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 272000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0259 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 252000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0239 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 208000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0198 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 168000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0160 | |
| Number of shares held | CurrentQuarterInstant | 4019000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.3820 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 757900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 10498000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 104980 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 24277 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 11280177 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 104980 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 757900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 757900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0672 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 757900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 757900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0672 | |
| Cash and deposits | Prior1YearInstant | 10643000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 10908000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 7870000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 6808000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 1020000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 1169000000 | JPY |
| Work in process | Prior1YearInstant | 70000000 | JPY |
| Work in process | CurrentQuarterInstant | 90000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 760000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 755000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |